Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 24331-24340 Newer>

The Motley Fool July 6, 2007 Rick Aristotle Munarriz	Chumps at Champps The Champps Americana restaurant chain is going out for a lot less than the $6.95 price tag that it started out the calendar year at. The price is also well off last year's high of $8.29 and the low teens that it peaked at five years ago.
The Motley Fool July 6, 2007 Brian Orelli	Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing.
The Motley Fool July 6, 2007 Emil Lee	A Brass Ring at Zale? Despite the company's powerful brand name in a decent industry, shares are languishing near three-year lows. So, could Zale be a bargain?
The Motley Fool July 6, 2007 Alyce Lomax	Time for a Slice of Panera? When mulling Panera as an investment idea, a forward P/E ratio of 20 doesn't exactly sound cheap, considering the continued uncertainty and the recent cut to second-quarter guidance.
The Motley Fool July 6, 2007 Steven Mallas	Mr. Softy's Extended Embarrassment Microsoft pays big bucks to fix Xbox 360 glitches. This goes far beyond a reddening of the corporate face. Microsoft stakeholders must endure a charge roughly valued between $1.05 billion and $1.15 billion.
The Motley Fool July 6, 2007 Toby Shute	Auto Sales Skid: So What? Lower sales may aid GM and Ford's return to profitability. Investors, take note.
The Motley Fool July 6, 2007 Brian Lawler	Medicines Decides Not to Share The Medicines Company reacquires its own drug. Until now, privately held European specialty pharma Nycomed has marketed Angiomax in Europe. Investors, take note.
The Motley Fool July 6, 2007 Tom Taulli	Dueling Fools: Salesforce.com Bull Investors, this company has earned its nosebleed valuation.
The Motley Fool July 6, 2007 Rick Aristotle Munarriz	Dueling Fools: Salesforce.com Bear Investors, don't overpay for Salesforce.com. You're better than that. Great company? You bet. Bad stock? Indeed.
The Motley Fool July 6, 2007 Tom Taulli	Dueling Fools: Salesforce.com Bull Rebuttal Salesforce.com has a strong brand, a killer application, a robust platform, and a customer breadth that sets it apart from its rivals. Investors, take note.
<Older 24331-24340 Newer> Return to current articles.